Studies have suggested that DOT1L can target the gene expression of epithelial-mesenchymal transition (EMT) promoters by cooperating with the c-Myc/p300 transcriptional activity complex, thereby playing an important role in the occurrence and development of breast cancer, which suggests that DOT1L is a potential therapeutic target for invasive breast cancer (Lee and Kong, 2015). Here, DOT1L is linked to invasive breast carcinoma.